← Back to all trials
Recruiting
NCT06872125
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Conditions: Dravet Syndrome
Sex: All
Ages: 2 Years – 17 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 170
Sponsor: Stoke Therapeutics, Inc
Location: Phoenix Children's Hospital Phoenix Arizona
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Eligibility Criteria
Key Inclusion Criteria:
1. Patients must be ≥2 and \
Source: ClinicalTrials.gov (NCT06872125). StuddyBuddy aggregates publicly available trial information.
